Get the Stockscreener App
79.06
0.29%
-0.23
After Hours:
78.88
-0.18
-0.23%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $79.06, with a volume of 34.37M.
It is down -0.29% in the last 24 hours and up +1.40% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$79.29
Open:
$79.245
24h Volume:
34.37M
Relative Volume:
2.21
Market Cap:
$204.27B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
11.51
EPS:
6.87
Net Cash Flow:
$17.04B
1W Performance:
-3.24%
1M Performance:
+1.40%
6M Performance:
-19.37%
1Y Performance:
-39.03%
1-Day Range:
$78.60
$79.92
1-Week Range:
$77.10
$81.35
52-Week Range:
$73.31
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
79.06 | 204.27B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
762.73 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
149.79 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
73.77 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.30 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.77 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Why the Market Dipped But Merck (MRK) Gained Today - Yahoo
Merck (MRK) Gains as CDC Agenda Omits Gardasil Dose Changes - GuruFocus
Merck stock up as CDC meeting excludes HPV shots (MRK:NYSE) - Seeking Alpha
Merck (MRK) Expands Deals with Chinese Pharma Companies - GuruFocus
Kennedy's new US vaccine panel to discuss measles shot for children - marketscreener.com
Merck Stock Analysis: Is Today’s Massive 2% Spike a Breakout? - Daily Chhattisgarh News
Merck: Phase 3 trial in prostate cancer - MarketScreener
Merck Doses First Patient in Phase 3 Trial of Prostate Cancer Drug Candidate - MarketScreener
Merck (MRK) Begins Phase 3 Trial for New Prostate Cancer Treatment | MRK Stock News - GuruFocus
Breakthrough Prostate Cancer Drug Enters Phase 3 Trial: New Hope for 31% Survival Rate Disease - Stock Titan
2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Dividend Growth Remains a Key Priority for Merck - Insider Monkey
Merck (MRK) Dips More Than Broader Market: What You Should Know - Nasdaq
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC
Supreme Court Decision Lets Fosamax Lawsuit Against Merck (MRK) Proceed - GuruFocus
Merck bid to stop Fosamax suit thwarted by Supreme Court - Seeking Alpha
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? - Nasdaq
Merck Manuals Launches AI-powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources - PR Newswire
Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT - Insider Monkey
Merck’s SWOT analysis: stock faces keytruda LOE challenge amid pipeline promise - Investing.com
Merck (MRK) Secures Landmark FDA Approval for Keytruda in Head and Neck Cancer - Daily Chhattisgarh News
Immuno-Oncology and Precision Medicine Trends Led by Merck & Pfizer Boost Gastric Cancer Market Growth - openPR.com
SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit - AOL.com
Merck (MRK) Boosted by Rising MMR Vaccine Demand Amid Measles Outbreaks - GuruFocus
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia
FDA Approves Merck's Keytruda for Head and Neck Cancer - GuruFocus
Merck's Keytruda gains additional indications in head and neck cancer - Seeking Alpha
Merck: FDA approves Keytruda for head and neck cancer - marketscreener.com
FDA Approves Merck's Anti-PD-1 Therapy - marketscreener.com
Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression - marketscreener.com
FDA Approves Merck's Keytruda for Specific Head and Neck Cancer | MRK Stock News - GuruFocus
Merck (MRK) Awaits EU Approval for New Pet Medicine - GuruFocus
Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs - marketscreener.com
Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs - marketscreener.com
Merck (MRK) Awaits EU Approval for Innovative Canine Drug | MRK Stock News - GuruFocus
RFK Jr.’s New Vaccine Panel Includes Two Paid Witnesses Against Merck - Bloomberg.com
Merck Animal Health gets EU backing for Numelvi tablets (MRK:NYSE) - Seeking Alpha
Merck’s canine dermatitis drug Numelvi gets positive EU opinion - Investing.com
Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs - StreetInsider
Breakthrough: EU Panel Backs Merck's Novel Dog Itch Treatment That Works From Day One - Stock Titan
Kalkine : Is Merck Set for Strong Payouts This Dividend Season Dow Jones Industrial Average - Kalkine Media
Exclusive-Kennedy’s new vaccine adviser was expert witness against Merck vaccine - The Mighty 790 KFGO
Controversy Surrounds Merck (MRK) Due to Vaccine Litigation Ties - GuruFocus
RFK Jr’s vaccine advisor has worked against Merck shot (MRK) - Seeking Alpha
Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine - marketscreener.com
Merck (MRK) Initiates Late-Stage Dengue Vaccine Trial - GuruFocus
Merck: Phase 3 trial for dengue vaccine - marketscreener.com
Merck begins late-stage trial for single dose dengue vaccine - Seeking Alpha
Merck (MRK) Launches Key Phase 3 Trial for Dengue Vaccine | MRK Stock News - GuruFocus
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merck Co Inc Stock (MRK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 30 '25 |
Option Exercise |
84.71 |
464 |
39,305 |
8,242 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
May 02 '25 |
Option Exercise |
83.26 |
381 |
31,722 |
8,464 |
| Romanelli Joseph | President, Human Health Int?l |
May 02 '25 |
Option Exercise |
83.26 |
2,262 |
188,334 |
24,061 |
| Romanelli Joseph | President, Human Health Int?l |
Apr 30 '25 |
Option Exercise |
84.71 |
2,063 |
174,757 |
22,816 |
| Larson Betty D | EVP, Chief HR Officer |
Apr 30 '25 |
Option Exercise |
84.71 |
11,350 |
961,458 |
11,350 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 25 '25 |
Option Exercise |
58.08 |
5,000 |
290,400 |
12,040 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 25 '25 |
Sale |
82.76 |
4,262 |
352,723 |
7,778 |
0.16%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):